Phase 3 equivalence RCT in 412 patients with HER2-positive early or locally advanced breast cancer: neoadjuvant biosimilar TQB2440 matched reference pertuzumab for total pCR (58.9% vs 58.1%; RR 1.02), with similar safety.
RCTn = 412
Wang et al. TQB2440 compared with reference pertuzumab for HER2-positive, ER/PgR-negative, early or locally advanced breast cancer: a multicenter, randomized, double-blind, parallel-controlled, phase III equivalence trial